Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Rheumatology

Is Colchicine Safe During Pregnancy for FMF?

At a Glance

Yes, it is safe and highly recommended to continue taking colchicine for Familial Mediterranean Fever (FMF) during pregnancy and breastfeeding. Stopping colchicine increases the risk of severe FMF flares, which can cause preterm birth, miscarriage, and serious maternal complications.

Yes, the current medical consensus is that colchicine is safe to continue during both pregnancy and breastfeeding for women with Familial Mediterranean Fever (FMF) [1][2]. In fact, experts strongly advise against stopping your medication [3]. Discontinuing colchicine during pregnancy is dangerous because an FMF flare can trigger severe complications, including premature labor or miscarriage [4][5]. If you are planning to conceive, it is highly recommended to speak with your care team first to ensure your FMF is fully stabilized before pregnancy [6].

The Real Danger: Stopping Your Medication

Many young women diagnosed with FMF fear that taking medication will cause birth defects, leading some to stop taking colchicine without talking to their doctors. However, extensive clinical evidence shows that colchicine is not considered to be teratogenic (causing birth defects) at standard therapeutic doses [7][8]. The rate of congenital malformations in babies born to mothers taking colchicine for FMF is no different from the general population [2][9].

The real danger to your pregnancy comes from untreated FMF [1]. If you stop taking colchicine, your risk of experiencing an FMF flare increases significantly [4]. Uncontrolled systemic inflammation during a flare can lead to:

  • Increased risk of preterm birth or premature rupture of membranes [10][1].
  • Poor pregnancy outcomes, including a higher risk of miscarriage [4][2].
  • Increased risk of long-term maternal complications, such as AA amyloidosis, a serious condition where abnormal proteins build up in organs like the kidneys [5][11].

Continuing Treatment for a Healthy Pregnancy

The goal of treating FMF during pregnancy is to keep you entirely symptom-free and maintain normal levels of inflammatory markers in your blood [6][2]. When FMF is well-controlled with colchicine, the disease has no significant negative impact on your pregnancy, and you have an excellent chance of a healthy outcome [2][1].

To achieve this, you will need proactive, coordinated care:

  • Taking Your Medication: According to European League Against Rheumatism (EULAR) guidelines, you should continue taking your effective daily dose of colchicine throughout your entire pregnancy [3][6]. You should also follow standard pregnancy guidelines for taking prenatal vitamins with folic acid [2][12].
  • Extra Monitoring: Maintaining normal inflammatory markers means your high-risk OB/GYN or rheumatologist will likely order extra blood tests (such as CRP or SAA) throughout your pregnancy to catch early signs of inflammation before a flare happens [13].
  • If You Still Have Flares: If colchicine is not completely controlling your FMF, or if you experience a breakthrough flare while pregnant, contact your doctor immediately. Do not try to treat it on your own, as some common flare medications (like NSAIDs) may not be safe during pregnancy. If colchicine alone isn’t enough, doctors can sometimes use alternative treatments like interleukin-1 (IL-1) blockers (such as anakinra) to manage your condition [14].
  • Prenatal Testing: In the past, doctors sometimes recommended routine amniocentesis for women on colchicine due to unfounded fears about chromosomal abnormalities. Current medical consensus no longer recommends this invasive test simply because you are taking colchicine [7][8].

Breastfeeding While on Colchicine

You can safely breastfeed your baby while taking colchicine for FMF [1][15]. Research shows that colchicine is highly compatible with lactation, and maternal therapy during breastfeeding is regarded as safe [16][1].

While very small amounts of the medication may pass into breast milk, there is no evidence that it reaches clinically significant levels that would harm your infant [1][15]. Doctors actively encourage women with FMF to breastfeed while continuing their colchicine therapy [1]. As a standard precaution, you can simply monitor your infant for normal growth and rare signs of gastrointestinal upset, like diarrhea.

Common questions in this guide

Will taking colchicine during my pregnancy cause birth defects?
No, clinical evidence shows that colchicine does not cause birth defects at standard therapeutic doses. The rate of congenital malformations in babies born to mothers taking colchicine for FMF is no different from the general population.
What happens to my baby if I stop taking colchicine while pregnant?
Stopping your medication significantly increases your risk of an FMF flare. Uncontrolled inflammation from a flare can lead to severe pregnancy complications, including a higher risk of preterm birth, miscarriage, and maternal kidney damage.
Is it safe to breastfeed my baby while taking colchicine?
Yes, you can safely breastfeed while continuing your colchicine treatment for FMF. While very small amounts of the medication may pass into breast milk, there is no evidence that it reaches levels that would harm your baby.
How will my FMF be monitored while I am pregnant?
Your high-risk OB/GYN or rheumatologist will likely order extra blood tests throughout your pregnancy to check inflammatory markers like CRP or SAA. This proactive monitoring helps catch early signs of inflammation before a full flare happens.
What should I do if I have an FMF flare during pregnancy?
Contact your doctor immediately if you experience a breakthrough flare while pregnant. Do not try to treat the flare on your own, as some common over-the-counter medications like NSAIDs may not be safe during pregnancy.

Questions for Your Doctor

5 questions

  • How frequently will we run blood tests to monitor my inflammatory markers (like CRP or SAA) while I am pregnant?
  • Should my daily colchicine dosage remain exactly the same throughout my entire pregnancy, or do I need to adjust it or space it out differently?
  • Do you recommend a specific high-risk OB/GYN or maternal-fetal medicine specialist who has experience managing pregnancies with autoinflammatory conditions?
  • What are my safe treatment options if I experience a breakthrough FMF flare during pregnancy, given that I can't take certain standard medications like NSAIDs?
  • If colchicine is not fully controlling my symptoms right now, should we explore adding an IL-1 blocker before I try to conceive?

Questions for You

4 questions

  • How well-controlled has my FMF been over the last six months on my current colchicine dose?
  • Have I had my kidney function or protein levels checked recently to rule out early signs of amyloidosis before getting pregnant?
  • Have I clearly communicated my concerns about pregnancy and medication to both my rheumatologist and my gynecologist?
  • Am I ready to handle a potentially higher number of medical appointments and blood tests during my pregnancy to ensure my inflammation stays controlled?

References

References (16)
  1. 1

    Familial Mediterranean Fever in Pregnancy.

    Davidson A, Kuller JA, Dotters-Katz SK, Wood RL

    Obstetrical & gynecological survey 2024; (79(10)):611-616 doi:10.1097/OGX.0000000000001316.

    PMID: 39437379
  2. 2

    Association between basal proteinuria levels and pregnancy outcomes in familial Mediterranean fever.

    Iskender D, Kara O, Ozturk Kaymak A, et al.

    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 2020; (40(8)):1102-1105 doi:10.1080/01443615.2019.1700944.

    PMID: 32270724
  3. 3

    A Case of Familial Mediterranean Fever With Severe Attacks During Withdrawal Bleeding After Controlled Ovarian Hyperstimulation.

    Tatara M, Tanaka Y, Takebayashi A, et al.

    Cureus 2024; (16(12)):e76168 doi:10.7759/cureus.76168.

    PMID: 39840158
  4. 4

    Arterial stiffness in Familial Mediterranean Fever: correlations with disease-related parameters and colchicine treatment.

    Sgouropoulou V, Stabouli S, Trachana M

    Clinical rheumatology 2019; (38(9)):2577-2584 doi:10.1007/s10067-019-04601-6.

    PMID: 31127463
  5. 5

    Familial Mediterranean fever: overview of pathogenesis, clinical features and management.

    Migita K, Asano T, Sato S, et al.

    Immunological medicine 2018; (41(2)):55-61 doi:10.1080/13497413.2018.1481579.

    PMID: 30938266
  6. 6

    Fertility in male patients with familial Mediterranean fever and paternal effect of FMF on pregnancy outcomes and complications.

    Parlar K, Azman FN, Sıcakyüz SL, et al.

    Internal and emergency medicine 2025; (20(3)):797-803 doi:10.1007/s11739-025-03881-y.

    PMID: 39907917
  7. 7

    Familial Mediterranean Fever: Assessing the Overall Clinical Impact and Formulating Treatment Plans.

    Manna R, Rigante D

    Mediterranean journal of hematology and infectious diseases 2019; (11(1)):e2019027 doi:10.4084/MJHID.2019.027.

    PMID: 31205631
  8. 8

    Familial Mediterranean Fever.

    Ozdogan H, Ugurlu S

    Presse medicale (Paris, France : 1983) 2019; (48(1 Pt 2)):e61-e76 doi:10.1016/j.lpm.2018.08.014.

    PMID: 30686512
  9. 9

    Growth and pubertal development in children with familial Mediterranean fever under colchicine therapy.

    Bayrak Demirel O, Arik SD, Kandemir T, et al.

    European journal of pediatrics 2025; (185(1)):45 doi:10.1007/s00431-025-06711-7.

    PMID: 41460254
  10. 10

    Familial Mediterranean fever: perspective on female fertility and disease course in pregnancy from a multicenter nationwide network.

    Yurdakul FG, Bodur H, Çay HF, et al.

    Rheumatology international 2024; (44(10)):2117-2127 doi:10.1007/s00296-023-05436-w.

    PMID: 37658927
  11. 11

    Familial mediterranean fever and long-term cardiovascular disease burden.

    Magen E, Aamar S, Merzon E, et al.

    The American journal of medicine 2026; doi:10.1016/j.amjmed.2026.01.006.

    PMID: 41520806
  12. 12

    Familial Mediterranean fever in childhood: a single-center experience.

    Barut K, Sahin S, Adrovic A, et al.

    Rheumatology international 2018; (38(1)):67-74 doi:10.1007/s00296-017-3796-0.

    PMID: 28828621
  13. 13

    Monogenic autoinflammatory disease-associated cardiac damage.

    Wei Q, Sun L

    Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2023; (72(8)):1689-1693 doi:10.1007/s00011-023-01771-7.

    PMID: 37563333
  14. 14

    [IL-1-blockade with Anakinra during pregnancy : Retrospective analysis of efficacy and safety in female patients with familial Mediterranean fever].

    Venhoff N, Voll RE, Glaser C, Thiel J

    Zeitschrift fur Rheumatologie 2018; (77(2)):127-134 doi:10.1007/s00393-017-0354-9.

    PMID: 28752409
  15. 15

    The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.

    Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al.

    Annals of the rheumatic diseases 2016; (75(5)):795-810 doi:10.1136/annrheumdis-2015-208840.

    PMID: 26888948
  16. 16

    The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.

    Giat E, Ben-Zvi I, Lidar M, Livneh A

    International journal of molecular sciences 2022; (23(7)) doi:10.3390/ijms23073956.

    PMID: 35409316

This page provides educational information about managing Familial Mediterranean Fever during pregnancy and breastfeeding. Always consult your high-risk OB/GYN or rheumatologist before making any changes to your medication or colchicine dosage.

Get notified when new evidence is published on Familial Mediterranean fever.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.